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Introduction: The Medtronic SelectSecureTM pacing lead (SS) has theoretical advantages compared 
to conventional (C) transvenous pacing leads (PL). The study purpose was to determine whether 
differences in electrical function and lead survival exist between these PL in a large data set of 
pediatric and congenital patients.   
Methods: A multicenter historical longitudinal cohort study was performed comparing SS and CPL 
performance over a 72-month follow-up (FU). Ten centers provided data for both SS and CPL, 
matched for age, implanted pacing chamber, time period of implantation, and presence of heart 
disease.  
Results: The cohort consisted of 141 subjects in each group. No statistical differences were observed 
in age, gender, presence of heart disease, or pacing indication. Atrial and ventricular capture 
thresholds were stable throughout FU and higher in the SS group (atrial: 0.75 ± 0.02 vs. 0.5 ± 0.04 V, 
ventricular: 1.0 ± 0.04 vs. 0.75 ± 0.04 V), p< 0.001. Group PL sensing thresholds did not differ. The SS 
group required greater energy to pace (atrial: 0.57 ± 0.05 vs. 0.32 ± 0.02 mJ, ventricular: 0.83 ± 0.05 
vs. 0.56 ± 0.06 mJ), p=0.001. Early lead dislodgement and phrenic nerve stimulation were greater in 
the SS group (p=0.03). Long-term lead survival was high and similar between the two groups, p=0.35.  
Conclusions: Long-term survival of both PL was high with a low fracture rate. The SS had excellent 
electrical function but did show higher capture thresholds and increased energy to pace; these 
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Introduction   
Technologic development of cardiac pacemakers has advanced to such a high level of manufacturing 
precision that very few failures of the pulse generator are seen clinically today. At present, the 
weakest link in the cardiac pacing system continues to be the pacing leads. Historically, older 
generation transvenous pacing leads were fraught with high capture thresholds, sensing failure, 
insulation breaks and conductor fractures.1-6 Previous studies reported transvenous pacing lead 
fracture rates in children between 5% and 17% over a follow-up of 2-5 years.1-6 Newer generation 
steroid eluting pacing leads have markedly decreased the frequency of subacute capture and sensing 
failure.5 However, the long-term survival of these pacing leads is still not described.  
 
Pacing lead malfunction can result from lead fracture (either in the insulation coating or the metal 
conductor), high capture thresholds, poor sensing characteristics, lead dislodgement or lead stretch 
from growth in children.2 Lead extraction and replacement is often required secondary to lead 
malfunction, need to upgrade from a pacing to ICD system, patient growth or infection. Removal of 
most currently available chronic pacing leads is complex, requiring expertise in pacing lead 
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Theoretically, the structural build of the Medtronic SelectSecure (Model 3830) (Minneapolis, MN) 
transvenous pacing may promote longevity and freedom from lead fracture, as well as ease of 
removal after development of lead malfunction.9 The SelectSecure pacing lead (4.1 Fr. outer lead 
body diameter) is lumenless and is composed of a MP35N conductor with hybrid insulation 
(polyurethane outer and silicone inner). The lead has a beclomethasone eluting-collar to improve 
pacing and sensing thresholds. The lack of a central lumen and the use of a conductor cable, rather 
than coil, allows for increased insulation redundancy, high tensile strength, and reduced bulk. 
 
This study hypothesized that this novel lumenless design would result in 1) improved lead survival, 2) 
equivalent sensing and capture characteristics, and 3) less complicated lead extraction compared to 
stylet-driven traditional transvenous pacing leads.   
Methods 
Study Population:  Ten pediatric electrophysiology centers participated in a historical parallel group 
longitudinal multicenter cohort study design to compare the performance of the lumenless 
SelectSecure (Model 3830) pacing lead with conventional active fixation stylet-driven pacing leads. 
Participating centers were chosen to have substantial experience in the techniques required for 
implanting the SelectSecure pacing lead, and also to have, in the same era, implanted conventional 
non-SelectSecure pacing leads. In total, 141 SelectSecure and 141 conventional pacing leads were 
used in our data analysis. 
 
All conventional pacing leads were required to have a bipolar configuration, steroid eluting low-
threshold electrode tip design, and active fixation mechanism, Table 1.  An attempt was made to 
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chamber of lead implantation and the presence/absence of congenital heart disease, at each center. 
Each center implanted both SelectSecure and conventional pacing leads. 
 
Each participating institution obtained IRB approval for enrolling subjects in this study. All data were 
de-identified and entered into a password-protected RedCap database, maintained at Children’s 
National Health System. 
 
Data Collection:  
Baseline data included: 1) subject demographics (date of birth, gender, race), 2) date of implant 
procedure, 3) pacing lead manufacturer and model number, 3) site of pacing lead position (atrial or 
ventricular, and location in the chamber if known), 4) electrophysiologic indication for pacing lead 
implantation, 5) presence and type of heart disease.  Lead initial performance data included 1) 
capture threshold (Volts), 2) sensing threshold (mV), 3) lead impedance (Ohms), and 4) 
complications at the time of implantation or within the first 30 days after implantation. 
 
Follow-up data collected every 12 months to the maximum time of follow-up included: 1) date of 
follow-up, 2) capture threshold (Volts), 3) paced pulse width, 4) sensing threshold (mV), 5) lead 
impedance (Ohms)and 6) complications during follow-up. Complications included: 1) cardiac 
perforation, 2) failure to capture, 3) failure to sense, 4) lead dislodgement, 5) phrenic nerve 
stimulation, 6) lead fracture or insulation breach with lead impedance out of range, and 7) venous 
thrombosis. If the implanted pacing lead needed revision, either for malfunction or upgrade (e.g. to 
an ICD lead), data were collected on whether the pacing lead was retained and abandoned, or 
extracted.  Extraction data collected included date of extraction, ease of extractability, method used 








Pacing Energy Calculation: The energy required for cardiac pacing was calculated from 
simultaneously measured pacing lead capture threshold, pulse width of stimulation and pacing lead 
impedance. Energy to pace was calculated for each subject at each time point of follow-up. The 
following formula was used to calculate the pacing energy at capture threshold: Energy = ((Voltage 
of stimulation)2 X Pulse Width)/ Impedance. Pacing energy was determined at a pulse width of 0.5 
msec. 
 
Statistical Analysis:  Analyses proceeded from baseline comparisons of comparability by lead study 
group (SelectSecure vs. conventional pacing lead) to longitudinal modeling allowing for comparative 
evaluation of electrical performance, complication and extraction rates over time.  Before 
conducting analyses of pacing lead electrical performance, the distribution of acute and chronic 
measurements was evaluated to determine whether the normality assumption was met to permit 
use of linear regression models. The distributions were not normally distributed and traditional data 
transformations failed to satisfy the normality assumption, p < 0.001. Therefore, parametric 
modeling was rejected, and quantile regression analysis based on qreg in Stata 15 was used instead 
to estimate medians rather than means, which would be subject to greater influence of 
measurements that depart from normality.10 Time-to-event analyses based on Cox proportional 
hazards modeling was used to compare lead survival, freedom from failure and complications, and 
need for lead extraction.  Both models controlled for differences between groups at baseline and 
duration of follow-up, including evaluation of interactive effects of lead group by follow-up time.  
Analyses accounted for correlation due to matching of patients receiving SelectSecure and 




This article is protected by copyright. All rights reserved. 
 
7 
over time. Two-tailed p-values below 0.05 were considered statistically significant. Data were 
reported as median  standard error. 
 
Results 
Study population: The study cohort consisted on 141 subjects implanted with the SelectSecure 
pacing lead, and 141 patients in the conventional population. Demographics are shown in Table 2. As 
expected, no difference in age, gender, ethnicity or presence of congenital heart disease (Table 3) 
was found when comparing the two groups.  No significant differences were found in the indication 
for pacing lead implantation between the two groups (Table 4).  No difference in follow-up time 
between the two groups (58  2.2 vs. 57.7  2.1 months, p=0.92) was seen. SelectSecure pacing 
leads were implanted between January 2006 and September 2014.The conventional pacing leads 
were implanted between November 1999 and September 2014, with substantial overlap between 
the two pacing lead groups from 2006 to 2014. Study subjects ranged in age from 3 to 36 years of 
age, median ages in the SelectSecure and conventional pacing lead groups were 13.7 vs. 14.1 years, 
respectively, p=0.58. 
 
Conventional Pacing Lead Types: The manufacturer and model number for the conventional pacing 
leads are tabulated in Table 1. The majority (89%) were manufactured by Medtronic (Minneapolis, 
MN), and consisted of Model Numbers 4076 and 5076.   
 
Pacing Lead Position: The SelectSecure and conventional pacing lead groups were composed of 
similar number of implanted pacing leads in either the atrium or ventricle and in both chambers, 65, 
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Sites for atrial lead placement in the SelectSecure pacing group were the right atrial lead appendage 
(47), right atrial free wall (28), right atrial septum (13), left atrium (4), and not specified (17).  Sites 
for atrial lead placement in the conventional pacing lead group were right atrial lead appendage 
(61), right atrial free wall (18), right atrial septum (4), left atrium (4), and not specified (25). 
SelectSecure atrial pacing leads were placed more frequently at sites other than the right atrial 
appendage (49% vs. 30%), p=0.03.   
 
Sites for ventricular lead placement in the SelectSecure pacing group were the right ventricular apex 
(19), right ventricular outflow tract (5), right ventricular septum (35), right ventricular free wall (2), 
left ventricle (2), and not specified (13). Sites for ventricular lead placement in the conventional 
pacing lead group were right ventricular apex (30), right ventricular outflow tract (0), right 
ventricular septum (30), right ventricular free wall (4), left ventricle (2), and not specified (9). 
SelectSecure ventricular pacing leads were placed more frequently at sites other than the right atrial 
apex (70% vs. 55%), p=0.02. 
 
Pacing Lead Electrical Performance  
Acute Measurements: 
Acute Atrial and Ventricular Capture Thresholds: No significant differences were noted between the 
SelectSecure and the conventional pacing lead groups in the median acute atrial (0.70 ± 0.06 vs. 0.60 
± 0.04 Volts, p=0.14), and ventricular (0.46 ± 0.05 vs. 0.55 ± 0.04 Volts, p=0.15) capture thresholds.   
 
Acute Atrial and Ventricular Sensing Thresholds: No significant differences were noted between the 
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0.23 vs. 3.2 ± 0.21 mV, p=0.73) and ventricular (10.5 ± 0.89 vs. 9.8 ± 0.64 mV, p=0.69) sensing 
thresholds.    
 
Acute Atrial and Ventricular Pacing Lead Impedance Measurements: Acute atrial lead impedance 
was significantly higher in the SelectSecure (679.2 ± 23.2 ohms) compared to the conventional 
pacing lead group (614.9 ± 22.0 ohms, p=0.04). Acute ventricular pacing lead impedance did not 
differ between the SelectSecure (744.6 ± 23.0 ohms) and the conventional pacing lead group (727.1 




Chronic Atrial and Ventricular Capture Thresholds (> 1-month Follow-up): Median chronic atrial 
and ventricular pacing lead capture threshold measurements remained stable over a 72-month 
follow-up period, Figures 1A and 1B.  Chronic atrial and ventricular pacing thresholds were higher in 
the SelectSecure compared with the conventional pacing lead group, p<0.001 and p<0.001, 
respectively. Time-averaged chronic atrial pacing thresholds for the SelectSecure pacing leads were 
0.75 ± 0.02 V vs. conventional pacing lead group 0.5 ± 0.04 V, p< 0.001. Time-averaged chronic 
ventricular pacing thresholds for the SelectSecure pacing leads were 1.0 ± 0.04 V vs. the 
conventional pacing lead group 0.75 ± 0.04 V, p< 0.001.  Time-averaged values were integrated over 
a 72-month period of follow-up. Voltage threshold was determined at 0.5 msec. 
 
Chronic Atrial and Ventricular Sensing Thresholds (> 1-month Follow-up): Median chronic atrial and 
ventricular pacing lead sensing threshold measurements were stable over a 72-month follow-up 








Chronic Atrial and Ventricular Pacing Lead Impedance Measurements (> 1-month Follow-up): None 
of the SelectSecure pacing leads had an impedance considered out of operative range (< 200 or > 
2000 ohms).The pattern of changes in chronic atrial pacing lead impedance measurements over time 
differed between the SelectSecure and conventional pacing lead groups, p=0.016, figure 2A. Chronic 
atrial pacing lead impedance decreased over time in the SelectSecure group and remained stable in 
the conventional atrial pacing lead group. Impedance measurements were within the normal 
operative range (< 200 or > 2000 ohms). 
 
Likewise, changes in chronic ventricular pacing lead impedance measurements over time differed 
between the SelectSecure and conventional pacing lead groups (p=0.045), figure 2B. As with atrial 
pacing leads, chronic ventricular pacing lead impedance decreased over time in the SelectSecure 
group and decreased much more slowly in the conventional ventricular pacing lead group. 
 
These differences are reflected in the time-averaged impedance measurements for the atrial and 
ventricular pacing lead groups, which were higher in the SelectSecure group vs. the conventional 
pacing lead group during a 72-month period of observation. Time-averaged impedance 
measurements for the atrial pacing lead groups were higher in the SelectSecure group (523.4 ± 6.2 
Ohms) vs. the conventional pacing lead group (476.1 ± 6.7 Ohms), p< 0.05. Time-averaged 
ventricular lead impedance measurements were higher in the SelectSecure group (550.0 ± 8.1 
Ohms) vs. the conventional pacing lead group (486.6 ± 8.3 Ohms), p< 0.05.  
 
Energy for Chronic Atrial and Ventricular Pacing (>1-month Follow-up): Changes in calculated atrial 
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and conventional pacing lead groups, p< 0.001, figure 3A. Time-averaged chronic atrial pacing lead 
energy was higher in the SelectSecure than in the conventional pacing lead group, 0.57 ± 0.05 vs. 
0.32 ± 0.02 mJ, respectively, p<0.001.  
 
Long-term changes in calculated ventricular pacing lead energy increased slightly over time in both 
groups (p=0.048) and differed between the SelectSecure and conventional pacing lead groups, 
p=0.045, figure 3B. The time-averaged chronic ventricular pacing lead energy in the SelectSecure 
group was higher than observed in the conventional pacing lead group, 0.83 ± 0.05 vs. 0.56 ± 0.06 
mJ, respectively, p=0.001.  
 
Pacing Lead-Related Complications.  
Early Complications Occurring at Time of Pacing Lead Implantation and During the First Month of 
Follow-up: Complications occurred more commonly in the SelectSecure group in the first month 
following pacing lead implantation (19 vs. 8, p=0.03). Complications included lead dislodgement (7 
vs. 2), lead injury during sheath splitting (1 vs. 0), phrenic nerve stimulation (8 vs. 2), pericardial 
effusions (1 vs. 3), ventricular oversensing (2 vs. 0), and pneumothorax (0 vs. 1).  
 
Late Pacing Lead Complications Occurring After 1-month of Follow-up: Long-term complications 
during pacing lead follow-up did not differ between the SelectSecure (8) and the conventional pacing 
lead group (10), p=0.35, Table 5.  
The complication rate per 1000-person months of follow-up was not statistically different between 
the SelectSecure (0.78; 95% CI = 0.35 to 1.74) and the conventional pacing lead group (1.11; 95% CI = 
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Pacing Lead Survival Analysis: No difference was noted in the follow-up rate of lead complications 
up to 72 months of follow-up, p=0.50. The overall complication rate was low, 0.95 per 1000-person 
months of follow-up. A Kaplan-Meier plot of pacing lead survival free from complications was shown 
in figure 4.  
 
Pacing lead survival was separately analyzed by need for pacing lead extraction. While the 
SelectSecure pacing lead group showed a modest increase in risk for undergoing lead extraction 
(hazard ratio = 1.28), this was not statistically different from the conventional pacing lead group 
(p=0.70). 
 
Pacing Lead Extraction:  Sixteen pacing leads were extracted, 11 SelectSecure and 5 conventional 
pacing leads. The conventional leads were manufactured by Medtronic (model 5076, n=3, and 4076, 
n=2). Extraction in the SelectSecure lead group was performed using simple traction (10) and a laser 
sheath (1). Indications for lead extraction were dislodgement (9), oversensing (1), and phrenic nerve 
stimulation (1). Average implant duration was 18 ± 21 months. Indications for pacing lead extraction 
in the conventional group were fracture (2), failure to capture (2) and non-specified malfunction (1). 
Average implant duration was 36 ± 27 months. Extraction was performed using simple traction (3) 
and a laser sheath (2). No complications occurred during any of the extraction procedures.  
 
Discussion 
The data from this study confirm previous reports that the SelectSecure pacing lead has excellent 
acute and long-term capture and sensing thresholds in both the atrium and ventricle 9, 11-16 Two 
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impedance changes in SelectSecure leads. 11, 13 Bansal et al found statistically significant decreases in 
atrial capture threshold, atrial lead impedance and ventricular lead impedance. However, significant 
increases in ventricular capture threshold were found. Chronic atrial and ventricular sensing 
thresholds were stable. In contrast, Garnreiter et al reported somewhat different long-term changes 
in atrial and ventricular capture and sensing thresholds.11 Statistically significant increases in atrial 
and ventricular capture thresholds, P wave and R wave amplitudes were noted. Statistically 
significant decreases in the atrial and ventricular lead impedance measurements were appreciated.  
Collectively, these two studies along with findings of this study revealed a consistent decrease in 
atrial and ventricular lead impedances over time. The data from this study reconcile the directional 
opposite changes in atrial and ventricular capture and sensing thresholds reported between Bansal 
et al.13, and Garnreiter et al.11 Subsequent to 1 month of follow-up chronic atrial and ventricular 
capture and sensing thresholds were stable in the SelectSecure pacing lead group.  
 
What might be the long-term implications of the higher capture threshold and increased pacing lead 
impedance for the SelectSecure pacing lead group? Despite having a higher chronic pacing lead 
impedance, which can be advantageous in decreasing the energy to pace, we observed a larger 
longitudinal decrease in pacing lead impedance in the SelectSecure group compared with the 
conventional pacing lead group. The SelectSecure pacing lead group also demonstrated a 
consistently elevated capture threshold compared with the conventional pacing lead group, which 
may shorten battery life. Calculated energy to pace using simultaneously measured capture 
thresholds, pulse width and lead impedances (figure 3 A and B), suggested that the SelectSecure 
pacing lead may increase pacing energy requirements, thereby potentially reducing pacemaker 
battery longevity. Pacemaker longevity projections were performed using each pacing lead system 
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VVI pacing at 50%, 2) VVI pacing at 100%, and 3) DDD pacing (atrial pacing - 25% and ventricular 
pacing – 100%). A two-fold safety margin was programmed into the longevity calculator. The 
weighted average heart rate over the age range of our study population was calculated at 85/min. 
The pacemaker used for the calculations had one of the most efficient internal circuitry energy 
drains. The SelectSecure pacing lead group in the DDD model had a shorter mean device survival by 
0.7 years, and in the VVI paced 100% model a shorter mean survival by 0.6 years, reinforcing the 
possible clinical importance of the data provided regarding higher pacing energy requirements in the 
SelectSecure pacing group. To put this into perspective, we reviewed literature on the extension of 
device longevity promoted using software developments aimed at maximizing battery longevity - 
Capture Management (minimizing voltage output) and AV search hysteresis (limiting ventricular 
pacing).17,18 Average extension of device longevity by these advanced pacing algorithms was 
between 6-8 months, a difference similar in magnitude to the decrease in device longevity 
associated with the SelectSecure pacing lead compared with the conventional pacing lead group.  
 
The SelectSecure pacing lead provided flexibility for alternative site pacing; 49% of the SelectSecure 
atrial pacing leads and 70 % of SelectSecure ventricular pacing leads were implanted outside of the 
right atrial appendage for the atrial lead and outside of the right ventricular apex for the ventricular 
lead. Flexibility in lead site placement may be preferable in patients with congenital heart disease in 
whom the right atrial appendage anatomy may be distorted after open heart surgery or when 
considering alternative sites for lead placement to help improve cardiac hemodynamics. Karpawich 
et al highlighted the importance of the site of right ventricular pacing on paced ventricular function 
and being able to implant the ventricular pacing lead at alternative sites outside the right ventricular 
apex.19 His bundle pacing using SelectSecure pacing leads is becoming an alternative to traditional 








The SelectSecure pacing lead had very favorable long-term survival, with an estimated failure rate of 
0.78 per 1,000-person months of patient follow-up. Lead fracture was extremely uncommon (2/141 
pacing leads) in either group. This finding was in contrast to older case series of long-term pacing 
lead survival in pediatric patients which have suggested vulnerability of transvenous pacing leads to 
lead fracture. Olgun et al. noted a 7.3% transvenous pacing lead failure rate over a 5-year follow-up 
period.1 Most of the lead fractures occurred in active fixation leads. Fortescue et al noted multiple 
modes for failure of transvenous pacing leads – insulation break, lead fracture, high thresholds, 
stretch and late dislodgement with an actuarial survival of only 82% at 5 years.2 Silvetti et al. 
reported their experience with endocardial pacing in neonates and infants and noted a 10% failure 
rate (one early dislodgement and 1 late threshold rise).3  
 
Few studies have compared the performance of the SelectSecure pacing lead with conventional 
design stylet-driven pacing leads. Garnreiter et al. compared the performance of SelectSecure pacing 
leads against a thin transvenous stylet-driven pacing lead, the St. Jude model 1488 active fixation 
steroid eluding bipolar pacing lead.11 The average length of follow-up was 26 +/- 19 months. Nine 
complications (5%) occurred in the SelectSecure pacing lead group (poor capture threshold – 4, lead 
dislodgement – 3, pocket infection – 1, and phrenic nerve stimulation -1). In contrast, 20% of the 
control St Jude model 1488 pacing leads had complications – lead fracture (12), poor capture 
threshold (4), lead noise (2), lead dislodgement (1), and extracardiac pacing (1). Similar to the data 
reported by Garnreiter et al.11, overall lead survival of the SelectSecure lead in this study did not 
differ from the conventional pacing lead group. In the report by Garnreiter et al, freedom from atrial 
lead complications (SelectSecure and conventional pacing leads) over 5 years was between 95 and 
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this study the freedom from lead complication at 5 years in the SelectSecure pacing lead population 
was 96% and for the conventional pacing lead group was 94%. These results suggest the robustness 
of the SelectSecure lead design as well as improvement in the reliability of the conventional pacing 
leads compared to data reported on older pacing lead designs. 
 
Of note, however, lead dislodgement was found more frequently in the SelectSecure (11/141) 
pacing lead group.  Lead dislodgment was reported by five of the ten participating centers. There are 
several explanations for this. This may be related to the complexities of using an implant sheath and 
sheath splitter. Centers reporting lead dislodgement were independently queried, and thought that 
lead dislodgement occurred early in their experience and involved structural heart disease cases. 
Lack of adequate lead slack resulted in late dislodgement secondary to lead stretch from patient 
growth. Early lead dislodgement may be lessened using some lessons reported by Redfearn et al.21 
and Shali et al.22 Using a rabbit animal model for testing electrical characteristics that might predict 
successful pacing lead implantation, Shali et al showed that monitoring the current of injury 
response to lead implantation provided insight into lead stability.22 The magnitude (amplitude of ST 
segment elevation) and the duration of persistence of the current of injury predicted whether the 
lead was just in contact with the myocardium, partially or fully rotated and advanced into the heart 
tissue. Current of injury persisted longer for leads fully rotated and advanced into the myocardium 
compared to partially rotated leads (26.5  62.8 min vs. 5.6  2.0 min, p,0.05). Paying more attention 
to the implant electrogram dynamics, particularly the current of injury, may provide the implanter 
with better insight into whether the SelectSecure pacing lead tip has been fully rotated into the 
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While the numbers were small in this study, the SelectSecure pacing lead was easily extracted using 
simple traction in 10 of 11 patients, suggesting an advantage for implanting this lead in case of 
future need for pacing lead extraction secondary to lead failure or need for lead substitution. In the 
study reported by Garnreiter et al., nine SelectSecure pacing leads required extraction.11 All were 
successfully extracted using manual traction with counterclockwise rotation. From a population of 
22 attempted SelectSecure pacing lead extraction procedures, Shephard et al. were able to extract 9 
SelectSecure pacing leads using simple traction alone; however, 7 required the use of polypropylene 
sheaths and 6 needed a cutting sheath; average lead implant time was 4.1 years.8 Early data suggest 
an advantage for the SelectSecure pacing lead in facilitating easier lead removal if needed. 
 
This study revealed the high reliability of pacing in children using either the SelectSecure pacing lead 
or the conventional pacing lead group. Freedom from complications was similar between the 
groups. The mechanism for lead failure however differed between the two groups. Implantation of 
the SelectSecure pacing lead required a technique different from stylet-driven pacing leads. The 
more technically advanced challenges of implanting the SelectSecure pacing lead resulted in a higher 
early dislodgment rate, which has also been reported in previous studies.11, 12,16 Of note, a low lead 
fracture rate was seen in both the SelectSecure and the conventional pacing lead groups. 
 
What potential attributes can be ascribed to the SelectSecure pacing lead? The SelectSecure pacing 
lead did provide flexibility in positioning the lead in alternative sites for pacing, and ease of 
extraction. Alternative sites of pacing can have definite hemodynamic advantage. Pacing lead 
survival rate was high with a low fracture rate. The SelectSecure pacing lead demonstrated excellent 
electrical function. Not assessed in this study were differences between the SelectSecure and 
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Bharmanee et al. would suggest an advantage for the SelectSecure pacing lead in allowing better 
atrioventricular valve function and less likelihood of venous compromise.23  
 
Limitations: Study limitations include historical data collection based primarily on record review. 
This study was not a randomized comparison of the SelectSecure pacing lead with conventional 
stylet-driven pacing leads or any specific stylet-driven lead design. The choice of which lead to 
implant in any patient was up to the discretion of the operator and introduces potential biases. 
However, the study design was not intended to compare the SelectSecure pacing lead with a specific 
conventional style-driven pacing lead model, but a group of the usual conventional stylet-driven 
pacing leads deployed in pediatric pacing practice. The authors felt it unfair to restrict the 
conventional group to a specific lead design in which data would be parsed introducing other bias 
choosing lead designs with superior or inferior performance compared with the SelectSecure group. 
In reality, functional pacing lead outcomes are not merely dependent on a specific pacing lead build, 
but are influenced as much by other factors such as 1) patient characteristics - presence of heart 
disease, type of heart disease, patient age at implant, 2) chamber of implantation, and 3) 
operator/implant center characteristics. To account for these other influences, each SelectSecure 
pacing lead from each center was matched with a conventional pacing lead implanted in a 
comparable aged-subject, matched by presence or absence and type of associated heart disease, 
matched by the cardiac chamber of implantation – atrium or ventricle from that center, and 
matched by “era” of implantation.  
 
Conclusions: The SelectSecure pacing lead did provide flexibility in positioning the lead at alternative 
sites for pacing, and ease of extraction. Since the SelectSecure pacing lead lumenless design is 
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related to a learning curve inherent to its deployment. Long-term pacing lead survival and 
complication-free survival in both the SelectSecure and conventional pacing lead groups was high 
with a low fracture rate, which is different from previously reported pacing lead longevity studies in 
children and young adults. Both the SelectSecure and conventional pacing lead groups 
demonstrated excellent electrical function but the SelectSecure pacing lead group did exhibit slightly 
higher capture thresholds and increased calculated energy to pace over time.  
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Figure 1: Longitudinal changes in capture threshold to pace for the atrial and ventricular pacing leads 
(Volts). A. Longitudinal changes in atrial lead capture thresholds. Atrial capture threshold was higher 
in the SelectSecure pacing group, p<0.001. B. Longitudinal changes in ventricular lead capture 
thresholds. Ventricular capture threshold was higher in the SelectSecure pacing group, <0.001. 
SelectSecure pacing lead data are illustrated in red, and conventional pacing leads in blue. Line 
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Figure 2: Longitudinal changes in atrial and ventricular pacing lead impedance (Ohms). 
A. Atrial leads. Atrial pacing lead impedance was higher in the SelectSecure pacing group, p<0.016. B. 
Ventricular leads. Ventricular pacing lead impedance was higher in the SelectSecure pacing group, 
p=0.045. SelectSecure pacing lead data are illustrated in red, and conventional pacing leads in blue. 
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Figure 3: Longitudinal changes in threshold energy to pace for the atrial and ventricular pacing leads 
(mJ).  A. Atrial leads. Atrial lead energy to pace was higher in the SelectSecure pacing group, 
p<0.001. B. Ventricular leads. Ventricular lead energy to pace was higher in the SelectSecure pacing 
group, p=0.001. SelectSecure pacing lead data are illustrated in red, and conventional pacing leads in 
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Figure 4: Kaplan-Meier plot of pacing lead survival free from complications. SelectSecure pacing lead 
data are illustrated in red and conventional pacing lead data are shown in black. No significant 
difference noted between the two groups up to 72 months of follow-up, p = 0.50.  
Number of leads at risk provided at bottom of graph. 
 
 
Table 1: Manufacturer and Pacing Lead Model Numbers Implanted in the Conventional 
Pacing Lead Group  
Conventional Pacing Leads                                            
 
     
Number  
of Leads 
      
   Guidant  
    4469          2 
   4470      4 
   4471        2 
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4472        1 
   4878        1 
    
St. Jude Medical 
    1888TC           2 
   2088TC         3 
    
Medtronic 
              
         
        4076                                                                                      47 
     5076                                                                                      76 
     5086                                                                                        3 
 
 




SelectSecure CPL      Total p-value 
 
N % N % N % 
 
Total 141 100 141 100 282 100 
  
Gender 
      
0.12 
Male 84 59.6 71 50.4 155 55 
 Female 57 40.4 70 49.6 127 45 
 
        Race 
      
0.77 
American Indian/Alaska Native 0 0.0 1 0.7 1 0.4 
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Black or African American 18 12.8 12 8.5 30 10.6 
 White/Caucasian 104 73.8 108 76.6 212 75.2 
 Hispanic 13 9.2 15 10.6 28 9.9 
 Other 2 1.4 1 0.7 3 1.1 
 Not Available 2 1.4 1 0.7 3 1.1 
 
        Age at Implant                                                                                                                                                             
      
0.82
<6 yrs. 9 6.4 7 5.0 16 5.7 
 6 - <12 yrs. 42 29.8 48 34.0 90 31.9 
 12 - <18 yrs. 57 40.4 57 40.4 114 40.4 
 18 - 36 yrs. 33 23.4 29 20.6 62 22.0 
  
CPL = Conventional Pacing Lead Group 
 
Table 3: Presence of Congenital and Non-Structural Heart Disease  
 
 
 SelectSecure %      CPL % Total % p-value 
 







Atrial Septal Defect                             4 5.2 9 11.3 13 8.3  
Aortic Stenosis 5 6.5 7 8.8 12 7.6 
 Aortic Arch Anomaly 2 2.6 5 6.3 7 4.5 
 Aortic Insufficiency 0 0.0 3 3.8 3 1.9 
 AV Septal Defect 7 9.1 10 12.5 17 10.8 
 Double Outlet Right Ventricle 4 5.2 1 1.3 5 3.2 
 Ebstein’s Anomaly 4 5.2 0 0.0 4 2.5 
 Hypoplastic Left Heart 1 1.3 0 0.0 1 0.6 
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Pulmonary Artery Atresia 2 2.6 0 0.0 2 1.3 
 Pulmonary Stenosis 0 0.0 1 1.3 1 0.6 
 Single Ventricle 1 1.3 1 1.3 2 1.3 
 Tetralogy of Fallot 14 18.2 8 10.0 22 14.0 
 Total Anomalous PV Return 4 5.2 4 5.0 8 5.1 
 Tricuspid Atresia 1 1.3 0 0.0 1 0.6 
 Truncus Arteriosus 1 1.3 2 2.5 3 1.9 
 Ventricular Septal Defect 7 9.1 9 11.3 16 10.2 
 D-TGA 12 15.6 14 17.5 26 16.6 
 L-TGA 7 9.1 4 5.0 11 7.0 
 







Dilated 6 42.9 7 46.7 13 44.8 
 Hypertrophic 6 42.9 7 46.7 13 44.8 
 Other 2 14.3 1 6.7 3 10.3 
 







Myocarditis 0 0.0 1 50.0 1 12.5 
 Cardiac Transplantation 3 50.0 0 0.0 3 37.5 
 Infectious Endocarditis 1 16.7 0 0.0 1 12.5 
 Other 2 33.3 1 50.0 3 37.5 
        
 
AV = atrioventricular, CPL = Conventional Pacing Lead Group, 
TGA = transposition of great arteries 
 
Table 4: Indications for Pacing 
       
 
SelectSecure % CPL % Total % p-value 
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Sick Sinus Syndrome (Tachy-Brady 
Syndrome) 
21 12.7 11 7.4 32 10.2 
 Sinus Node Dysfunction / Sinus Pauses 33 20 30 20.3 63 20.1 
 Second Degree AV Block 22 13.3 17 11.5 39 12.5 
 Complete AV Block 62 37.6 62 41.9 124 39.6 
 Atrial Rhythm detection for DDD ICD 23 13.9 19 12.8 42 13.4 
 Other 4 2.4 9 6.1 13 4.2 
 
     
        
CPL = Conventional Pacing Lead Group 
ICD = implantable cardioverter defibrillator, DDD = dual chamber 
 
Table 5: Complications Reported Greater than 1 Month Following Pacing Lead Implantation  
 
Type of Complication SelectSecure       CPL       Total 
 
N % N % N % 
Total Participants Reporting a 
Complication 6 4.4 9 6.4 15 5.3 
 
Total Complications Reported  8 5.8 10 7.2 18 6.4 
 
Type of Complication 
      Failure to Capture 2 1.4 3 2.1 5 1.9 
Lead Fracture 2 1.4 2 1.4 4 1.4 
Significant Increase in Capture 
Threshold 1 0.7 0 0.0 1 0.3 
Lead Dislodgement 3 2.1 0 0.0 3 1.1 






This article is protected by copyright. All rights reserved. 
 
30 
Failure to Sense 0 0.0 2 1.4 1 0.4 
Other 1 0.7 1 0.7 2 0.7 
       
 
CPL = Conventional Pacing Lead Group 
Fisher's Exact Test, p=0.35 
 
 
